.svg){kind=icon}
Cannabichromene, commonly abbreviated CBC, is one of the many naturally occurring cannabinoids produced by Cannabis sativa.
It receives far less attention than THC or CBD, but researchers have been studying CBC for decades. Current areas of interest include inflammatory signaling, pain pathways, transient receptor potential channels, neural cells, microbial activity, and interactions with the broader endocannabinoid system.
The evidence is intriguing—but still developing.
Most research involving CBC remains laboratory or animal research, and human clinical evidence is limited.
For Florida medical cannabis patients, CBC should therefore be viewed as an emerging minor cannabinoid, not as a proven treatment for pain, inflammation, neurological disorders, or another medical condition.
What Is Cannabichromene?
CBC is a naturally occurring phytocannabinoid.
Like THC, CBD, and CBG, it originates from cannabinoid biosynthesis inside the cannabis plant.
The pathway begins with CBGA, or cannabigerolic acid.
A specialized enzyme known as CBCA synthase can convert CBGA into cannabichromenic acid:
CBGA → CBCA
CBCA can then lose carbon dioxide through decarboxylation:
CBCA → CBC
Heat can accelerate this conversion.
This is similar to the relationships between:
THCA → THC
and
CBDA → CBD
Is CBC Intoxicating?
CBC is generally considered non-intoxicating.
It does not strongly activate CB1 receptors in the same way delta-9 THC does.
CB1 activation in the central nervous system is one of the main mechanisms responsible for THC-related intoxication.
CBC's receptor profile appears considerably more complicated.
Researchers are investigating its activity at several other molecular targets, particularly TRP ion channels.
A product containing CBC can still be intoxicating if it also contains substantial THC.
Patients should therefore review the complete cannabinoid profile rather than assuming the presence of CBC makes the entire product non-intoxicating.
CBC and TRP Channels
One of the most interesting areas of CBC pharmacology involves transient receptor potential channels.
Laboratory research has identified CBC activity at:
- TRPA1
- TRPV1
- TRPV3
- TRPV4
These channels participate in functions involving:
- Pain signaling
- Temperature sensation
- Inflammation
- Cellular calcium
- Sensory responses
CBC has shown particularly strong experimental activity at TRPA1.
That finding helps explain why researchers continue studying CBC in pain and inflammatory models.
However, activity at a receptor or ion channel does not automatically establish a therapeutic effect in humans.
CBC and Pain Research
Pain is one of the most frequently studied areas of CBC research.
Animal experiments have evaluated CBC in models involving:
- Acute pain
- Inflammatory pain
- Neuropathic pain
- Chemotherapy-related neuropathy
Some studies have reported reductions in pain-related behavioral responses after purified CBC administration.
Researchers have proposed possible involvement of:
- TRPA1
- CB1-related signaling
- Adenosine A1 receptors
- Potassium channels
More recent cell research has also found that CBC can alter TRPV1-related calcium signaling in sensory neurons.
These findings provide potential mechanisms for future research.
They do not establish CBC-containing cannabis as a pain treatment.
CBC and Inflammation
CBC has also demonstrated anti-inflammatory activity in several experimental systems.
Animal research has explored conditions involving:
- Tissue inflammation
- Intestinal inflammation
- Inflammatory hypermotility
- Respiratory inflammation
Interestingly, some studies suggest CBC's inflammatory effects do not depend entirely on classical CB1 or CB2 cannabinoid receptors.
That illustrates an important point about cannabis pharmacology:
Not every cannabinoid acts primarily through CB1 and CB2.
Researchers continue investigating pathways involving TRP channels, MAPK signaling, and other cellular mechanisms.
CBC and the Gastrointestinal System
One early area of CBC research involved intestinal inflammation and motility.
In animal models, CBC reduced abnormal gastrointestinal movement triggered by inflammation while having little effect on normal intestinal motility.
Researchers found that these effects were not clearly dependent on traditional cannabinoid receptors.
This makes CBC interesting for gastrointestinal research.
But animal models of inflammatory bowel activity should not be interpreted as evidence that CBC treats Crohn's disease, ulcerative colitis, or another gastrointestinal disorder in humans.
Controlled human trials would be needed.
CBC and Neural Cell Research
CBC has also attracted attention in neurological research.
One frequently cited study investigated neural stem and progenitor cells.
These cells can contribute to the development and maintenance of nervous-system tissues.
Experimental CBC exposure increased viability of certain neural progenitor cells.
Researchers have also examined CBC in models involving:
- Neuroinflammation
- Astrocyte activity
- Neuronal signaling
- Seizure-related pathways
These findings are early-stage.
They do not establish CBC as a treatment for Alzheimer's disease, epilepsy, traumatic brain injury, or another neurological condition.
CBC and Mood Research
Animal studies have reported antidepressant-like behavioral effects involving CBC.
That has led some cannabis resources to describe CBC as a “mood cannabinoid.”
That description is premature.
Behavioral tests in rodents are useful research tools, but they are not equivalent to diagnosing or treating depression in people.
There is currently insufficient human evidence to conclude that CBC improves mood or treats depression.
Patients should be cautious with products marketed around claims such as:
“CBC boosts happiness.”
The research does not support that level of certainty.
CBC and Antimicrobial Research
Cannabichromene has also demonstrated antimicrobial activity under laboratory conditions.
Researchers have investigated cannabinoids against certain bacteria and fungi.
These experiments help identify possible biological properties and may guide future drug-development research.
But laboratory antimicrobial activity does not mean a CBC-containing cannabis product can treat an infection.
Bacterial, fungal, and other infections require appropriate medical diagnosis and treatment.
What Human CBC Research Exists?
Human CBC research is much more limited than research involving THC or CBD.
One Phase I study evaluated a standardized oral cannabis formulation containing CBD, THC, and CBC.
Researchers measured how CBC appeared in the bloodstream after repeated dosing.
CBC doses ranged from approximately 6.6 mg to 26.4 mg per day.
The study demonstrated that CBC could be measured systematically in human plasma and provided early pharmacokinetic information.
It was not designed to prove that CBC treats a disease.
CBC Has Also Appeared in Combination Trials
A large randomized sleep study tested several non-intoxicating cannabinoid formulations.
One formulation combined:
- 15 mg CBD
- 15 mg CBN
- 5 mg CBC
Participants in several treatment groups reported improvement in sleep disturbance.
However, adding CBC and CBN did not significantly outperform CBD-containing comparison formulations.
More recently, CBC has also appeared as one component in multi-cannabinoid research involving chronic pain.
These studies are useful but have an important limitation:
They do not isolate CBC.
If multiple cannabinoids are administered together, researchers cannot automatically attribute an outcome to CBC alone.
CBC and the Entourage Effect
CBC is often mentioned in discussions about the cannabis entourage effect.
Preclinical research has tested CBC in combination with THC and reported additive or potentially synergistic effects in some experimental pain models.
Other experiments have produced different results.
This illustrates why “entourage effect” should not be treated as a universal rule.
Each combination needs to be studied directly.
CBC + THC may behave differently from CBC + CBD or CBC + CBN.
Human evidence remains particularly limited.
Is CBC Common in Cannabis?
CBC can occur naturally in cannabis, but mature commercial products usually contain much less CBC than THC.
Several factors influence concentration:
- Genetics
- CBCA synthase activity
- Plant maturity
- Harvest timing
- Decarboxylation
- Processing
- Extraction
CBC concentrations can also vary significantly between product formats.
For example, an extracted vaporizer formulation may contain more measurable CBC than some whole-flower batches.
Current laboratory testing is therefore the most reliable way to know whether CBC is present.
Green Dragon Florida Products With CBC
The following products are included to illustrate how CBC appears within complete cannabinoid profiles.
They are not recommendations for treating pain, inflammation, sleep problems, or neurological conditions.
Magnus Lemon Cherry Gelato Cartridge — Englewood
Magnus Lemon Cherry Gelato Cartridge is currently listed around 84.4% total THC, 0.229% total CBD, and 2.78% total terpenes.
Its current Full Lab Data lists approximately 0.773% CBC.
The same profile contains approximately 3.05% CBG and 0.22% CBN, demonstrating how several minor cannabinoids can coexist within a THC-dominant product.
Everyday Alien Sunset All-in-One — Tallahassee Monroe
Everyday Alien Sunset All-in-One is currently listed around 79% total THC, 0.33% total CBD, and 6.0% total terpenes.
Its current laboratory profile contains approximately 0.37% CBC, along with measurable CBG, CBGA, CBN, CBD, and CBDA.
This is a useful example of why a full cannabinoid panel provides more information than the headline THC percentage.
Everyday Cherry Runtz Live Wax — Crystal River
Everyday Cherry Runtz Live Wax is currently listed around 79.8% total THC, 0.165% total CBD, and 7.04% total terpenes.
The current public menu does not expose a verified CBC value for this batch.
Patients specifically interested in CBC should review the Full Lab Data rather than assuming a concentrate contains CBC based on its cultivar or product format.
Product availability and laboratory measurements can change by Green Dragon Florida location and batch.
The Green Dragon Takeaway
CBC is one of the more interesting minor cannabinoids currently being investigated.
Research has identified potential activity involving:
- TRPA1 and TRPV channels
- Pain pathways
- Inflammatory signaling
- Neural cells
- Gastrointestinal function
- Antimicrobial activity
Some human studies have measured CBC exposure or included CBC within multi-cannabinoid formulations.
But direct clinical evidence remains limited.
For medical cannabis patients, the most accurate description is:
CBC is an emerging cannabinoid with promising preclinical research, not an established medical treatment.
Patients interested in CBC should review current Full Lab Data, consider the complete cannabinoid profile, and avoid assuming that a small CBC percentage reproduces the doses or effects studied in research.